Middle East & Africa Biologics Market – Size, Outlook, Trends and Forecast (2024 – 2032)

The diseases that are treated by biologics are cancer, rheumatoid arthritis, and many more rare diseases for which there were no previous treatment options. Compared to the more traditional drug, such as aspirin, this new class of medicine is inherently more complex and cannot be synthesised by chemicals means alone. Any medical product that is originated from living organisms is considered to be biologic products.

The Middle East & Africa Biologics Market Size & Growth:

The Middle East & Africa biologics market was valued to be nearly $XX billion in 2017 and is expected to reach over $XX billion by the end of 2025 with a CAGR of XX% during the forecast period from 2019-2025. Key drivers driving the Middle East & Africa biologics market growth include increasing capital investment from critical players, rising prevalence of chronic diseases, growing demand & higher acceptability for innovative therapies and others. Increase in population & changes in social behaviour is contributing to a steady rise & costly long-term health problems. The middle class is increasing and the urbanisation fast-tracking, adopting a more inactive lifestyle. This is increasing obesity rates and leading many diseases with diabetes on top. Based on the World Health Organization report, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit, as population growth is expected to be most significant in developing nations. Biologics drugs are highly complex & required to control & maintain throughout the development & production process. This regulated environment & quality control procedures involve huge capital investment in the initial state of the process. Additionally, biologics are most susceptible to light, heat conditions, and need an extremely promising environment that is not available uniformly across the globe. In most emerging markets, currently, biologics have little presence. Stringent regulatory policies and high-capital investment coupled with limited patient access to reasonable biologics mainly in the developing countries owing to the increasing control and cost for accessing biologics are likely to obstruct the growth of the Middle East & Africa biologics market. Based on the Middle East & Africa biologics market outlook, cancer application market size is estimated to proliferate. Since the demand for usage of biologics is growing in cancer treatment.

The Middle East & Africa Biologics Market  Share:                                                                

The Middle East & Africa biologics market is classified by product, application and geography. By the product, the market in monoclonal antibodies segment of the biologics market is estimated to grow at the fastest CAGR during the forecast period. These antibodies are made by different immune cells that are all clones of a unique parent cell. These antibodies had monovalent affinity and bind to the same epitope and used to treat cancer. Regarding application, the market in cancer application of the biologics market is estimated to grow at the fastest CAGR during the forecast period. This growth can be due to increasing demand for biologics in the treatment of cancer to kill cancer cells by body immune system.

Concerning geography, the market is segmented into Middle East & Africa. The Middle East is predicted to be a dominant market in the biologics market during 2019 – 2025. Africa is said to be the fastest growing market regarding biologics. Growing conciseness regarding health & increasing population is boosting the biologics market.

The Middle East & Africa Biologics Market Trends:

• August 2018, Takeda is banking on a super target-sized biologic plant in Brooklyn Park.
• July 2018, Revolutionary biologics for asthma with high benefits.

The Middle East & Africa Biologics Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have a complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
• Regional and the Middle East & Africa diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact on altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
  • GlaxoSmithKline
  • Sanofi
  • Merck & Co
  • Novo Nordisk
  • Roche
  • Shalina Healthcare
  • Pfizer Inc.
  • Johnson & Johnson
  • Alcon.
  • Bayer AG
  • Teva
  • Astellas Pharma Inc.